The search for new peptides to be used as analgesics in place of morphine has been mainly directed to develop peptide analogues to have higher biological stability and receptor selectivity.
Introduction
The endogenous opioid peptides have been studied extensively since their discovery aiming to develop effective drugs for the treatment of pain in humans (1) . The opioid peptides are significantly implicated in antinociceptive processes. Their action is modulated by opioid receptors, widely distributed in the CNS (2) . They belong to the class of G-protein coupled receptors, and divided into three types, mu ( ), kappa (κ) and delta (δ) (3) . One of the major drawbacks of using natural opioid peptides as analgesics is their poor receptor specificity that has been attributed to a number of factors, primarily to the chemical structure and conformation (4) . Beside a partial receptor selectivity, a second important limitation to the use of native peptides as pharmacological tools is their rapid enzymatic degradation (5) . One of the remaining problems preventing the use of opioid peptides as drugs is poor bioavailability, which is due to the low penetration across various biological barriers, especially blood-brain barrier (BBB) (6) , which act as a barrier to unnecessary substances, and admits vital nutrients for proper function of the centeral nervous system (CNS) and possess many peptidases enzymes such as aminopeptidase, and arylamidase (7) . Several strategies to manipulate BBB transport processes have been developed including lipidization, chemical modifications of the N-terminal end, coupling of transport with post BBB metabolism and formation of potent neuroactive peptides, use of chimeric peptides in which a non-transportable peptide is chemically linked to a transportable peptide, and binding of circulating peptides to apolipoproteins (8) . Endogenous peptides generally have a short lifetime in vivo due to enzymatic biodegradation, and consequently have poor bioavailability in tissues. Therefore, it has been a challenge to improve the stability of an enkephalin while still maintaining its potency and selectivity (9) . The pharmacology of opioid peptids was greatly stimulated by Kosterlitz s discovery of two endogenous pentapeptides Met-enkephalin and Leu-enkephalin in 1975, where the pharmacological profile of Met-enkephalin Fig.(1) is similar to that of morphine, attempts to utilize this peptide as a therapeutic agent have been hindered by its polarity and metabolic lability (10) . 2) is steroid hormone have estrogenic activity synthesized by the action of aromatase enzymes on testosterone in the ovaries and placenta, and exert its pharmacological activity on the estrogen receptor (ER) which is member of nuclear receptors found intracellulary, and there are of two subtypes (α a n d β) ( 11) ; Have important role in the menstrual cycle, development of secondary sex characteristics, several metabolic (e.g. anabolic action), and prevent osteoporosis (12) .
Fig.(2) : Estrone.
As endogenous bioactive substances peptide and steroids play important roles in the normal physiology or disease processes of mammalian systems (13) . The linkers of the steroids and peptides may simulate the permissive action, where the effects of peptides enhanced by steroids through increasing their receptor numbers (14) , for example daily administration of 25 mg of estradiol benzoate to adult female rats for 9 days led to an approximately three fold increase in number of pituitary thyrotropinreleasing hormone (TRH) binding site (15) , estrogen treatment in vivo lead to an increase sensitivity of the thyroid-stimulating hormone (TSH) contents (16) , the interaction between opioid peptides and steroids were observed e.g. kyotorphin (Tyr-Arg-OH) which is isolated from bovine brain with morphine like analgesic effects, its analgesic activity and duration of analgesia significantly enhanced when linked to steroids (e.g., estrone, and hydrocortisone) (13) . In addition to their analgesic effects, endogenous peptides are involved in the regulation of many disorders like stress response (17) , of several behavioral and emotional effects, such as dependence, alcohol and other drugs consumption (18) . They are also effective in a large number of physiological functions: gastrointestinal, cardiovascular, respiration and immunological responses, pregnancy, etc (19) .
Materials and Methods
Estrone, L-amino acids and Boc-protected L-amino acids are purchased from fluka AG/Switzerland and all solvents are of analar type without need further purification; Melting points determined by Thomas Hoover apparatus England by capillary method, and ascending thin layer chromatography TLC was run on Keisl gel GF 254 type60 Merk, W. Germany to check the progression of reaction and purity. IR spectra were recorded in KBr film FTIR in college of science, university of Baghdad. Elemental microanalysis done by using Carloarba elemental analyzer, amino acids analysis Hitachi amino acid analyzer Model 6-3800, optical rotation performed with Perken Elmer apparatus, and H 1 -N M R r e s o l u t i o n i n d e u t e r i u r a t e d d imethyl solfoxide using tetramethyl silane as a standard done by using Bruker spectrophotometer 300 MHz, all done at Cleveland clinical Foundation Learner Research Institute-France.
The final analogue purified by using gel filtration on sephodex LH-20 column eluted with 0.1N acetic acid done in college of pharmacy, university of Baghdad. (20) 90 10 0.5
The protective pentapeptide was prepared by use of Stepwise elongation, in which the amino acids are connected step-by-step via solution method, where dicyclohexylcarbodiimide (DCC) was used as coupling agent and 1-hydroxybenzotriazole (HOBt) was used as coupling agent and prevents racemization in the peptide formation (21) . Also we use fragment condensation when synthesis long peptides in smaller sections, were later coupled to form the overall peptide (22) . It is desirable to have a range of protecting groups available that can be selectively orthogonally removed, two protecting groups are said to be orthogonal protection when they are removed by totally different classes of reagents (e.g. one by acid and the other by base), the butyloxycarbonyl (BOC) group a widely used protective group that is generally removed from the N-terminal by using moderate-strong acids e.g. triflouro acetic acid (TFA) and is stable under the basic conditions, while the C-terminal protected by methyl ester which removed by using strong base e.g. NaOH and is stable under the moderate-strong acidic conditions (19) . The O-alkylation of estrone with ethyl bromoacetate and sodium ethoxide provided ethyl estrone-3-oxymethylenecarboxylated which treated with 1M KOH and 1M HCL respectively to obtain estrone-3-oxymethylene carboxylic acid which coupled with NH TyrGly Gly phe-met OMe ester by amide bond in the presence of DCC and HOBt to offer Cterminal protective pentapeptide-estrone, which saponified and acidified by using 1N NaOH, and 1N HCL to give the goal analogue (20, 21) .
Synthesis

Synthesis of (Gly OMe ester) (Comp. 1)
A suspension of glycine (8mmol, 600 mg) in absolute methanol, was cooled down to 15°C then thionyl chloride was added dropwise (8mmol, 0.63 ml). (the temperature should be keep below 10°C).
The reaction mixture was left at 40°C for three hours, then refluxed for three hours and left at room temperature overnight.
The solvent was evaporated to dryness in vacuum, redissolved in methanol and evaporated. This process was repeated several times to ensure complete removal of excess thionyl chloride.
The residue was collected and recrystallized from methanol-ether (23) . Yield percent, physical appearance, melting point, R f value, and IR interpretation werelisted in Table ( 2).
Synthesis of (BOC Tyr Gly OMe ester). (Comp. 2)
To a stirred solution of BOC-Tyr (5 mmol, 1.4 g) in DMF, NMM (5mmol, 0.55ml) was added with stirring for 10 minutes. Then (5 mmol, 445 mg) of (Comp. 1) previously dissolved in DMF was also added, and the mixture was cooled down to (−10°C). HBT (10 mmol, 1.35 g) and DCC (5 mmol, 1.03 g) were added with stirring, which was continued for 2 days at 0°C and then at room temperature for 5 days. N,N Dicyclohexyl urea (DCU) was filtered, and washed with ethyl acetate. The filterate was concentrated under vacuum, the residue was mixed with ethyl acetate, the excess DCU which was still adhesive on the peptide residue was precipitated out and filtered, and the clear filterate washed twice with 5% sodium carbonate solution, 0.1N HCl, once with water, and with saturated sodium chloride solution. The ethyl acetate layer was dried with anhydrous sodium sulphate and evaporated in vacuum.
The resulted product was collected, recrystallized from methanol-ether (23) . Yield percent, physical appearance, melting point, R f value, and IR interpretation werelisted in Table ( 2).
Synthesis of (Boc-Tyr-Gly-OH). (Comp. 3).
Compound (2) (3 mmol, 1.057 g) was dissolved in minimum volume of dioxane : water (5:1) at 18°C, 1N NaOH (4.5 mmol, 4.5 ml) was added dropwise over a period of 30 minutes. The reaction was allowed to proceed for additional 3 hours, at a temperature range 18 22°C, during the course of the reaction the hydrolysis was checked by TLC until the disappearance of the starting material.
The reaction mixture was acidified with 1N HCl (4.5mmol, 4.5ml) in an equivalent amount to that of 1N NaOH and ice-water was added to get a faint yellow precipitate. The peptide was then filtered, dried, and recrystallized from ethyl acetate-ether (23) . Yield percent, physical appearance, melting point, R f value, and IR interpretation werelisted in Table ( 2).
Synthesis of (BOC Tyr-Gly Gly OMe ester). (Comp.4)
To a stirred solution of (2 mmol, 676 mg) of compound (3) in DMF, NMM (2mmol, 0.22 ml) was added with stirring for 10 minutes, then (2 mmol, 178 mg) of (Comp. 1) previously dissolved in DMF was also added, and the mixture was cooled down to 10°C. HBT (4 mmol, 540 mg) and DCC (2mmol, 412 mg) were added with stirring, which was continued for 2 days at 0°C and then at room temperature for 5 days, then continue the work as in the synthesis of compound (2) .
Yield percent, physical appearance, melting point, R f value, and IR interpretation werelisted in Table ( 2).
Synthesis of (BOC Tyr-Gly Gly OH). (Comp. 5)
Compound (4) (1.2 mmol, 491 mg) was dissolved in minimum volume of dioxane : water (5:1) at 18°C 1N NaOH (1.8 mmol, 1.8 ml) was added dropwise over a period of 30 minutes, the reaction was allowed to proceed for additional 3 hours, at a temperature range 18 22°C. during the course of the reaction the hydrolysis was checked by TLC until the disappearance of the starting material then continue the work as in the synthesis of compound (3).
Synthesis of (Met OMe ester) (Comp. 6).
A suspension containing (2.5 mmol, 372.5 mg) of methionine in methanol was cooled down to 15°C, then thionyl chloride (2.5 mmol, 0.2 ml) was added dropwise, then continue the work as in the synthesis of compound (1) .
Synthesis of (Boc Phe Met OMe ester). (Comp. 7).
To a stirred solution of (2mmol, 326mg) of compound (6) in DMF, NMM (2 mmol, 0.22 ml) was added with stirring for 10 minutes, then (2 mmol, 530 mg) of Boc Phe, already dissolved in DMF was also added and the mixture was cooled down to 10°C. HOBt (4 mmol, 540 mg) and DCC (2 mmol, 412 mg) were added with stirring, which was continued for 3days at 0°C and then at room temperature over 4 days; Then continue the work as in the synthesis of compound (2) .
Synthesis of (NH 2 Phe Met OMe ester). (Comp. 8).
Compound (7) (1.2 mmol, 493 mg) was dissolved in dichloromethane, then 1.2 ml of 90% solution of TFA in anisole was added dropwise with stirring at 0°C (the temperature should be kept at this low degree).
The mixture was left for 30 minutes at room temperature, then the completion of the deprotection was checked by TLC.
The solvents were removed under reduced pressure leaving a sticky product which after triturated several times with diethel ether a solid material obtained and was recrystallized from methanol-diethyl ether (3-1) (23) . Yield percent, physical appearance, melting point, R f value, and IR interpretation werelisted in Table ( 2).
Synthesis of (BOC Tyr-Gly Gly phe-met OMe ester). (Comp. 9)
To a stirred solution of compound (5) (0.75 mmol, 296.5 mg) in DMF, NMM (0.75 mmol, 0.08 ml) was added with stirring for 10 minutes. Then (0.75mmol, 232mg) of (Comp. 8) previously dissolved in DMF was also added, and the mixture was cooled down to 10°C. HOBt (1.5 mmol, 202.5 mg) and DCC (0.75mmol, 154.5mg) were added with stirring, which was continued for 2days at 0°C and then at room temperature for 5 days, then the work continue same as synthesis of compound (2) .
Yield percent, physical appearance, melting point, R f v a l u e , I R i n t e r p r e t a t i o n , e l e m e n t a lmicroanalysis, amino acids analysis were listed in Tables (2, 3 , and 4) respectively.
Synthesis of (NH2 Tyr-Gly Gly phe-met OMe ester). (Comp. 10).
Compound (9) (0.5 mmol, 344 mg) was dissolved in dichloromethane, then 0.5 ml of 90% solution of TFA in anisole was added dropwise with stirring at 0°C the reaction mixture was stirred for 30 minutes. The N deprotected pentapeptide was obtained after continue the work as synthesis of compound (8) .
Synthesis of ethyl estron-3-O-ylacetate (3-Ocarbethoxymethyl estrone) (Comp. 11)
Eestrone (1 mmol, 270 mg) was dissolve in minimum volume of [ethanol: tetrahydrofuran (THF)] (3.5:1) then sodium ethoxide (1.5 mmol; 0.75 ml of 2M in ethanol) and (3 mmol, 500 mg, 0.4 ml) of ethyl bromoacetate were added, the reaction mixture refluxed for 24 hr; An additional portion of sodium ethoxide and ethyl bromoacetate was added and refluxed continued for 2hr and the completion of reaction checked by TLC, the reaction mixture quenched in saturated NaCL, the product isolation by (ethylacetate-THF; MgSO 4 ) after this the solvent evaporated by vacuum and triturate the sticky residue with hexane several times to remove the small amount of contaminated ethyl bromoacetate to get white crystals which recrystalized from acetone-hexane (20) . Yield percent, physical appearance, melting point, R f value, and IR interpretation werelisted in Table ( 2).
Synthesis of estrone-3-O-ylacetic acid (3-OCarboxymethylestrone) (comp. 12).
Compound (11) (0.66 mmol, 235 mg) was dissolved in 3.5ml of ethanol and (1 mmol, 1 ml) of a 1 M of potassium hydroxide solution was added, the reaction mixture was stirred overnight at room temperature, then the solvent evaporated, and the residual salt washed with ether. The washed residue was dissolved in water and acidified with 0.1 N of HCL. The product isolation with (ether-THF; MgSO 4 ) to gave crude acid which recrtylized from benzene-ethylacetate (20) . Yield percent, physical appearance, melting point, R f v a l u e , I R i n t e r p r e t a t i o n , e l e m e n t a lmicroanalysis, and 1 H-NMR results were listed in Tables (2, 3 , and 5) respectively.
Synthesis of estrone-3-O-acyl-tyr-gly-gly-phemet-O-methyl ester (comp. 13)
To a stirred solution of compound (12) (0.3 mmol, 98.5 mg) in DMF (5ml), NMM (0.33 mmol, 0.04 ml) was added with stirring for 10 minutes. Then (0.3mmol, 176mg) of (Comp. 10) previously dissolved in DMF was also added, and the mixture was cooled down to 10°C. HOBt (0.6 mmol, 81 mg) and DCC (0.3mmol, 62mg) were added with stirring, which was continued for 2days at 0°C and then at room temperature for 5 days then the work continue as synthesis of compound (2) (13) . Yield percent, physical appearance, melting point, R f v a l u e , I R i n t e r p r e t a t i o n , e l e m e n t a lmicroanalysis, amino acids analysis, and optical activity were listed in Tables (2, 3 , and 4) respectively.
Synthesis of estrone-3-O-acyl-tyr-gly-gly-phemet-OH (comp. 14 final analogue).
Compound (13) (0.2mmol, 180mg) was dissolved in minimum volume of dioxane: water (5:1) at 18°C 1N NaOH (0.3 mmol, 0.3 ml) was added dropwise over a period of 30 minutes. The reaction was allowed to proceed for additional 3 hours, at a temperature range 18 22°C. during the course of the reaction the hydrolysis was checked by TLC until the disappearance of the starting material.
The reaction mixture was acidified with 1N HCl (0.3 mmol, 0.3 ml, in an equivalent amount to that of 1N NaOH) and ice-water was added to get a faint yellow precipitate. The peptide was then filtered, dried, and recrystallized from ethyl acetate-ether (13) . Yield percent, physical appearance, melting point, R f v a l u e , I R i n t e r p r e t a t i o n , e l e m e n t a lmicroanalysis, amino acids analysis, and optical activity were listed in Tables (2, 3 , and 4) respectively.
Results and Discussion
The results shown in the tables (2, 3, 4, and 5) indicate that the final analogue was excellently synthesized by the conventional solution method as shown in scheme (1) where we use both stepwise elongation and segment condensation of amino acids sequences to obtain the desired peptide, which then bind to estrone by amide bond to gain the final analogue as shown in scheme (2) that may be increase the analgesic potency and duration of the opioid peptide itself due to permissive action between them (13) , also the estrone increase the lipophilicity of the opioid peptide and this will lead more bioavailability, and enzymes resistance. 
Conclusion
The estrone-met-enkephaline analogue was successfully synthesized by the conventional solution method and the structure formula of the analogue was consistent with the proposed structure and they proved after get the excellent fallowing techniques: TLC, melting point, IR, CHN, optical rotation, amino acid analysis, and 1 H-NMR.
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